Categories: News

Dalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity with RoboFil system in Toronto

A fully automated aseptic fill-finish platform delivers greater speed, flexibility, and quality for the manufacturing of clinical supplies and commercial products.

- Advertisement -

TORONTO, March 31, 2026 /PRNewswire/ — Dalton Pharma Services today announced the successful installation of its RoboFil™ aseptic powder fill-finish system at its Toronto, Canada facility. This fully automated, isolator-based platform expands Dalton’s aseptic powder fill-finish capacity and further strengthens the company’s position as a market leader.

- Advertisement -

Dalton’s RoboFil™ line is purpose-built for aseptic powder fill-finish programs where dose accuracy, process consistency, and sterility assurance are paramount. By combining robotic handling with isolator technology, the platform helps minimize the needs for operator interventions, a primary contamination risk in aseptic operations, while enabling rapid, efficient changeovers between vial formats. This flexibility supports both development-stage batches through to repeatable GMP production campaigns.

- Advertisement -

Dr. Jixing Wang, President of Dalton Pharma Services, said:

- Advertisement -

“RoboFil™ reflects Dalton’s commitment to investing in advanced technologies that enable our clients to execute aseptic powder fill-finish with confidence. This Annex 1–aligned robotic isolator platform expands both our capacity and our operational flexibility, supporting programs from early clinical supply through scalable commercial manufacturing.”

- Advertisement -

About Dalton Pharma Services: Dalton Pharma Services is a full-service Contract Development and Manufacturing Organization (CDMO) based in Toronto, Canada. With 37 years of proven performance, Dalton’s single-site model integrates API development and cGMP manufacturing, formulation, aseptic fill/finish, and in-house QC/microbiological testing under a unified Quality Management System (QMS). Powered by a globally diverse team representing 40+ nationalities, including 44 MS/PhDs, and supported by 3,000+ successful production campaigns, Dalton partners with biotech and pharmaceutical companies worldwide to accelerate life-enhancing therapies from development through commercial supply.

- Advertisement -

For more information, visit: Dalton Website

- Advertisement -

Media Contact
Muhammad Haris
Marketing Manager
mharis@dalton.com

- Advertisement -

Photo – https://mma.prnewswire.com/media/2944494/Dalton_RoboFil.jpg
Logo – https://mma.prnewswire.com/media/2944493/Dalton_Pharma_Services_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/dalton-pharma-services-expands-aseptic-powder-fill-finish-capacity-with-robofil-system-in-toronto-302728673.html

- Advertisement -

Recent Posts

Over 500 Leaders from Across More Than 50 Countries and Territories Attend 56th Annual World Trade Centers Association Global Business Forum in Philadelphia

Flagship WTCA event delivers high-impact sector insights and global business connections across industries NEW YORK,…

2 hours ago

EquiLend Acquires Finadium, Expanding Presence in Securities Finance Research & Consulting

Finadium to continue operating independently as a subsidiary of EquiLendNEW YORK, May 12, 2026 /PRNewswire/…

2 hours ago

MEXC Commits to $500M Guardian Fund Expansion, Acquires 1,000 BTC to Strengthen User Protection

VICTORIA, Seychelles, May 12, 2026 /PRNewswire/ -- MEXC, a pioneer in 0-fee digital asset trading,…

2 hours ago

Maveric Systems announces strategic brand positioning focused on Engineering Trust in AI-First Banking

CHENNAI, India and DALLAS, May 12, 2026 /PRNewswire/ -- Maveric Systems, a banking-exclusive technology specialist,…

2 hours ago

NYSE Content Update: Disney CEO Josh D’Amaro Rings Bell Ahead of Upfront Event

NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, May 12, 2026…

4 hours ago

Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer

European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and…

4 hours ago